Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).2024 · 2 citations
2. 2Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma2024 · 194 citations
3. 3Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece2024 · 7 citations
4. 4Current Novel Targeted Therapeutic Strategies in Multiple Myeloma2024 · 21 citations
5. 5Belantamab Mafodotin: From Clinical Trials Data to Real-Life ExperiencesEarly-Phase Clinical Trial · 2023 · 21 citations